U.S. flag

An official website of the United States government, Department of Justice.

NCJRS Virtual Library

The Virtual Library houses over 235,000 criminal justice resources, including all known OJP works.
Click here to search the NCJRS Virtual Library

Multisite Pilot Study of Extended-Release Injectable Naltrexone Treatment for Previously Opioid-Dependent Parolees and Probationers

NCJ Number
Substance Abuse Volume: 33 Issue: 1 Dated: January-March 2012 Pages: 48-59
Donna M. Coviello, Ph.D.; James W. Cornish, M.D.; Kevin G. Lynch, Ph.D.; Tamara Y. Boney, M.S.; Cynthia A. Clark, M.S.N., CRNP, APRN, BC; Joshua D. Lee, M.D., M.Sc.; Peter D. Friedmann, M.D., M.P.H.; Edward V. Nunes, M.D.; Timothy W. Kinlock, Ph.D.; Michael S. Gordon, D.P.A.; Robert P. Schwartz, M.D.; Elie S. Nuwayser, Ph.D.; Charles P. O'Brien, M.D., Ph.D.
Date Published
February 2012
12 pages
This study examined drug treatment options for opioid-dependent individuals.
A feasibility study was conducted to pilot test the ability of five sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders. (Published Abstract)